Using Resistance Data to Make Treatment Decisions
August 8, 2000
Data supporting the use of resistance testing as a tool for choosing new treatment combinations has been reported by STEP in past issues. The use of resistance testing is becoming more widespread, but there are still questions about how effective this testing is for determining a new combination.
Final results of the VIRA 3001 study were presented in a poster by Calvin Cohen, M.D. This study looked at people on a failing regimen with their first protease inhibitor. Part of the group used a phenotypic resistance test to decide which new drugs to try, and the other group changed drugs based on their providers' suggestions and their previous anti-HIV drug history. The data was reviewed to see if there was a difference in the number of people who were able to get viral loads below 400 copies. When the data was analyzed to include only the people who were still in the study at its conclusion (on-treatment analysis), the data showed that the group basing treatment decisions on phenotypic resistance testing had a better chance of getting their viral load below 400 copies.
This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.